Idexx Laboratories (IDXX) reached a significant support level, and could be a good pick for investors from a technical perspective. Recently, IDXX broke through the 20-day moving average, which suggests a short-term bullish trend.A well-liked tool among traders, the 20-day simple moving average offers a look back at a stock's price over a 20-day period. This is very beneficial to short-term traders, as it smooths out short-term price trends and gives more trend reversal signals than longer-term moving avera ...

From a technical perspective, Idexx Laboratories (IDXX) is looking like an interesting pick, as it just reached a key level of support. IDXX recently overtook the 50-day moving average, and this suggests a short-term bullish trend.The 50-day simple moving average is a widely used technical indicator that helps determine support or resistance levels for different types of securities. It's one of three major moving averages, but takes precedent because it's the first sign of an up or down trend.IDXX could be ...

Meta Platforms Inc (META) - 公司股价较前期高点下跌近20% [1] - 第三季度业绩表现积极 但第四季度营收指引为560亿至590亿美元 低于分析师预估的5721亿美元 [1] - 公司提高了2025财年的资本支出指引 [1] - 公司股价周一收盘下跌16%至63771美元 [6] S&P Global Inc (SPGI) - 公司第三季度业绩超预期 调整后每股收益为473美元 超过分析师预期的441美元 同比增长216% [2] - 公司股价在周一交易时段上涨2% 收盘报49702美元 [6] IDEXX Laboratories Inc (IDXX) - 公司股价突破2021年高点 第三季度业绩超预期并上调2025年业绩展望 [3] - 第三季度调整后每股收益为322美元 同比增长15% 超过313美元的普遍预期 [3] - 第三季度销售额为1105亿美元 超过1073亿美元的普遍预期 报告基础上增长13% 有机增长12% [4] - 业绩增长由伴侣动物群业务推动 报告增长14% 有机增长12% 以及家禽和奶制品业务收入报告增长17% 有机增长14% [4] - 公司股价周一大涨148% 收盘报72294美元 [6]

IDEXX Laboratories ( IDXX ) delivered a very strong quarter and exceeded expectations. With Cancer Dx and InVue , further growth is likely in the future, which is why I consider theMy primary area of concentration will be on identifying companies of exceptional caliber, with a proven ability to reinvest capital for impressive returns. Targeting those with a market capitalization of less than $10 billion, affords ample opportunities for growth. The ideal scenario is for these companies to demonstrate a long- ...

IDEXX Laboratories (NASDAQ: IDXX) extended its streak of earnings beats this morning, reporting Q3 results that topped both EPS and revenue expectations while raising full-year guidance. ...

财务业绩表现 - 第三季度调整后每股收益为322美元 超出分析师预期的314美元 [1] - 第三季度营收同比增长13%至11亿美元 超过市场普遍预期的107亿美元 [1] - 第三季度有机营收增长达到12% [1] - 营业利润率扩大100个基点至321% [2] 业务板块驱动因素 - 伴侣动物群组部门收入增长14% 引领整体增长 [2] - CAG诊断经常性收入增长11% 有机增长为10% [2] - IDEXX VetLab耗材需求强劲 报告基础上增长18% [2] - 当季投放超过1700台IDEXX inVue Dx分析仪 [2] - CAG诊断资本仪器收入因此增长74% [2] 未来业绩指引 - 公司上调2025年全年营收指引至427亿美元至430亿美元 相当于增长96%至103% [3] - 同时上调每股收益指引至1281美元至1301美元 高于市场普遍预期的1263美元 [3]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2025 OR IDEXX LABORATORIES, INC. (Exact name of registrant as specified in its charter) Delaware 01-0393723 (State or other jurisdiction of incorporation or organization) (IRS Employer Identification No.) (Address of principal executive offices) (ZIP Code) One IDEXX Drive Westbrook M ...

And we are back on halftime with final trades. Kate, you're up first. >> Yeah.My final trades are sponsored by the letter of K. K-shaped in the consumer. K-shaped in terms of the large caps versus the small caps. And K-shaped in terms of the less rate sensitive versus the rate sensitive given my view on inflation.>> Mr. . Steve Weiss. Meta.Look, Meta, you have to buy this one. It's down. It's almost in bare market territory. It's down almost 20% from the high.And uh so I think it's a buy right here. Carrie, ...

Vet visits are down, but growing revenue per visit is more than making up for it, the company says. ...

Shares of Idexx Laboratories (IDXX) broke out and catapulted to a record high Monday after the vet diagnostics outlet beat Wall Street's quarterly forecasts and boosted its 2025 outlook. Idexx also earned an adjusted $3.22 per share, ahead of projections for $3.12. Earnings grew 15%. In morning trades, Idexx stock ramped up more than 16% to 725.82. Shares touched their highest-ever point and broke out of a flat base with a buy point at 688.12, according to MarketSurge. Idexx Laboratories And Vet Visits The ...